Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Retinal Biologics Market, by Indication
1.4.2 Europe Retinal Biologics Market, by Drug Class
1.4.3 Europe Retinal Biologics Market, by Distribution Channel
1.4.4 Europe Retinal Biologics Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter’s Five Forces Analysis
Chapter 4. Strategies deployed in Retinal Biologics Market
Chapter 5. Europe Retinal Biologics Market by Indication
5.1 Europe Macular Degeneration Market by Country
5.2 Europe Diabetic Retinopathy Market by Country
5.3 Europe Others Market by Country
Chapter 6. Europe Retinal Biologics Market by Drug Class
6.1 Europe VEGF-A Antagonist Market by Country
6.2 Europe Others Market by Country
Chapter 7. Europe Retinal Biologics Market by Distribution Channel
7.1 Europe Hospital Pharmacy Market by Country
7.2 Europe Retail Pharmacy Market by Country
7.3 Europe Online Pharmacy Market by Country
Chapter 8. Europe Retinal Biologics Market by Country
8.1 Germany Retinal Biologics Market
8.1.1 Germany Retinal Biologics Market by Indication
8.1.2 Germany Retinal Biologics Market by Drug Class
8.1.3 Germany Retinal Biologics Market by Distribution Channel
8.2 UK Retinal Biologics Market
8.2.1 UK Retinal Biologics Market by Indication
8.2.2 UK Retinal Biologics Market by Drug Class
8.2.3 UK Retinal Biologics Market by Distribution Channel
8.3 France Retinal Biologics Market
8.3.1 France Retinal Biologics Market by Indication
8.3.2 France Retinal Biologics Market by Drug Class
8.3.3 France Retinal Biologics Market by Distribution Channel
8.4 Russia Retinal Biologics Market
8.4.1 Russia Retinal Biologics Market by Indication
8.4.2 Russia Retinal Biologics Market by Drug Class
8.4.3 Russia Retinal Biologics Market by Distribution Channel
8.5 Spain Retinal Biologics Market
8.5.1 Spain Retinal Biologics Market by Indication
8.5.2 Spain Retinal Biologics Market by Drug Class
8.5.3 Spain Retinal Biologics Market by Distribution Channel
8.6 Italy Retinal Biologics Market
8.6.1 Italy Retinal Biologics Market by Indication
8.6.2 Italy Retinal Biologics Market by Drug Class
8.6.3 Italy Retinal Biologics Market by Distribution Channel
8.7 Rest of Europe Retinal Biologics Market
8.7.1 Rest of Europe Retinal Biologics Market by Indication
8.7.2 Rest of Europe Retinal Biologics Market by Drug Class
8.7.3 Rest of Europe Retinal Biologics Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Novartis AG
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Acquisition and Mergers:
9.1.6 SWOT Analysis
9.2 Amgen, Inc.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Regional Analysis
9.2.4 Research & Development Expenses
9.2.5 SWOT Analysis
9.3 AbbVie, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Regional Analysis
9.3.4 Research & Development Expense
9.3.5 Recent strategies and developments:
9.3.5.1 Partnerships, Collaborations, and Agreements:
9.3.5.2 Approvals & Trials:
9.3.6 SWOT Analysis
9.4 Bayer AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 SWOT Analysis
9.5 Regeneron Pharmaceuticals, Inc.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Research & Development Expense
9.5.4 SWOT Analysis
9.6 Santen Pharmaceutical Co., Ltd.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 SWOT Analysis
9.7 Bausch Health Companies, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Approvals & Trials:
9.7.5.3 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Approvals & Trials:
9.8.6 SWOT Analysis
9.9 MeiraGTx Holdings plc
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 SWOT Analysis
9.1 Oxurion NV
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Research & Development Expenses
9.10.4 SWOT Analysis
Unique Offerings 